Abstract
A 41-year-old pregnant woman with multiple virological failures started darunavir, enfuvirtide, zidovudine and lamivudine at week 28 of pregnancy. During week 38, the patient had a viral load <400 copies/mL and a CD4 count of 180 cells/mm(3) (13%). The child was found to be in good health, with negative HIV-polymerase chain reactions at birth, at two and at six months.
MeSH terms
-
Adult
-
Antiretroviral Therapy, Highly Active*
-
CD4 Lymphocyte Count
-
Darunavir
-
Drug Resistance, Multiple, Viral
-
Drug Therapy, Combination
-
Enfuvirtide
-
Female
-
HIV Envelope Protein gp41 / administration & dosage
-
HIV Envelope Protein gp41 / therapeutic use*
-
HIV Fusion Inhibitors / administration & dosage
-
HIV Fusion Inhibitors / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / drug effects
-
Humans
-
Infant, Newborn
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / therapeutic use*
-
Pregnancy
-
Pregnancy Outcome
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use*
-
Treatment Outcome
-
Viral Load
Substances
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
HIV Protease Inhibitors
-
Peptide Fragments
-
Sulfonamides
-
Enfuvirtide
-
Darunavir